An Integrative miRNA-mRNA Expression Analysis Reveals Striking Transcriptomic Similarities between Severe Equine Asthma and Specific Asthma Endotypes in Humans. by Hulliger, Matthias F. et al.
genes
G C A T
T A C G
G C A T
Article
An Integrative miRNA-mRNA Expression Analysis
Reveals Striking Transcriptomic Similarities between
Severe Equine Asthma and Specific Asthma
Endotypes in Humans
Matthias F. Hulliger 1,2, Alicja Pacholewska 1,2,† , Amandine Vargas 3, Jean-Pierre Lavoie 3,
Tosso Leeb 2 , Vincent Gerber 1 and Vidhya Jagannathan 2,*
1 Swiss Institute of Equine Medicine, Department of Clinical Veterinary Medicine, Vetsuisse Faculty,
University of Bern, 3012 Bern, Switzerland; matthias.kraft@vetsuisse.unibe.ch (M.F.H.);
alicja.pacholewska@uk-koeln.de (A.P.); vinzenz.gerber@vetsuisse.unibe.ch (V.G.)
2 Institute of Genetics, Vetsuisse Faculty, University of Bern, 3012 Bern, Switzerland;
tosso.leeb@vetsuisse.unibe.ch
3 Faculty of Veterinary Medicine, University of Montreal, 3200 rue Sicotte, St-Hyacinthe, QC J2S 2M2, Canada;
amandine.vargas@umontreal.ca (A.V.); jean-pierre.lavoie@umontreal.ca (J.-P.L.)
* Correspondence: vidhya.jagannathan@vetsuisse.unibe.ch
† Current address: Institute for Translational Epigenetics, University Hospital Cologne,
50937 Cologne, Germany.
Received: 1 July 2020; Accepted: 24 September 2020; Published: 28 September 2020


Abstract: Severe equine asthma is an incurable obstructive respiratory condition affecting 10–15% of
horses in temperate climates. Upon exposure to airborne antigens from hay feeding, affected horses
show neutrophilic airway inflammation and bronchoconstriction, leading to increased respiratory
effort. The resulting implications range from welfare concerns to economic impacts on equestrian
sports and horse breeding. Immunological and pathophysiological characteristics of severe equine
asthma show important parallels with allergic and severe neutrophilic human asthma. Our study
aimed at investigating regulatory networks underlying the pathophysiology of the disease by profiling
miRNA and mRNA expression in lung tissue samples from asthmatic horses compared with healthy
controls. We sequenced small RNAs and mRNAs from lungs of seven asthmatic horses in exacerbation,
five affected horses in remission, and eight healthy control horses. Our comprehensive differential
expression analyses, combined with the miRNA–mRNA negative correlation approach, revealed a
strong similarity on the transcriptomic level between severe equine asthma and severe neutrophilic
asthma in humans, potentially through affecting Th17 cell differentiation. This study also showed
that several dysregulated miRNAs and mRNAs are involved in airway remodeling. These results
present a starting point for a better transcriptomic understanding of severe equine asthma and its
similarities to asthma in humans.
Keywords: RNA-seq; regulatory networks; differential expression analysis; Equus caballus; lung
tissue; immunology; precision medicine
1. Introduction
Severe equine asthma (sEA) is an incurable obstructive respiratory condition affecting
approximately 10% to 15% of horses in temperate climates [1]. When exposed to airborne antigens,
mainly during hay feeding, affected horses develop the characteristic signs of sEA exacerbation:
neutrophilic airway inflammation, bronchial hyperreactivity, bronchoconstriction, and mucus
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hypersecretion. These chronic or recurrent exacerbations manifest with coughing, exercise intolerance,
and increased respiratory effort. Marked clinical improvement with phases of disease remission are
observed with decreased exposure to allergens and irritants in stable dust [2]. However, complete
avoidance of the offending agents is often impossible, and medical treatment with corticosteroids and
bronchodilators becomes necessary to relieve acute asthma symptoms. Chronic changes and residual
airway obstruction related to airway remodeling persist in disease remission [3]. sEA is currently
incurable and its consequences range from substantial welfare concerns to negative economic effects on
equestrian sports and horse breeding [4]. Elucidation of the underlying pathophysiological mechanisms
of asthma in horses is needed to improve prevention and treatment of this condition. Importantly,
such advances may also improve our understanding of asthma in humans, as immunological and
pathophysiological characteristics of sEA show important parallels with allergic as well as severe
neutrophilic human asthma [5].
Asthma in humans has a prevalence of around 4.3% globally, and not only poses a significant threat
to human health, but also presents a massive economic burden [6,7]. Much of the pathophysiological
mechanisms of asthma are studied in experimental animal models (mostly rodents). However, sEA
offers one of the few spontaneous models of human asthma [4]. In order to improve the management
of sEA in horses as well as discover novel comparative information relevant to human asthma,
specific molecular pathways and mechanisms at the transcriptomic level need to be better understood.
The current evidence regarding the immunological basis of sEA is conflicting. There are data that support
both aspects of type I and type III hypersensitivities as well as involvement of the major immunological
pathways including Th1, Th2, and Th17 [8–11]. An immediate-phase response is lacking in sEA,
but affected horses characteristically show a delayed-phase allergic reaction to antigen challenge with
neutrophil recruitment to the bronchial lumen and mixed Th-cell responses [12]. Several studies have
reported a predominant Th2-type immune response (characterized by increased IL-4, IL-5, and IL-13
expression) [13–15] and evidence from genome-wide association studies (GWAS)tentatively supports
IL4R as a possible candidate gene [16], while other investigations reported a mixed Th1–Th2-type
response [17–19].
In human asthma, which is now recognized as a complex, heterogeneous disease group,
the intricate and intertwined gene–environment interactions [20] are being categorized and
assigned to sub-conditions with different clinical presentations (phenotypes) and diverse underlying
pathophysiological mechanisms (endotypes) [5,21]. Recently, transcriptomic analyses of bronchial
epithelium and of stimulated peripheral blood mononuclear cells (PBMC) have been performed in
sEA [9,22]. Differentially expressed genes, pathways, and networks were identified in the airway
epithelium of affected horses (e.g., MMP1, IL8, TLR4, and MMP9; neutrophil chemotaxis, immune,
and inflammatory responses; circadian rhythm dysregulation; and the sonic Hedgehog pathway)
that were also found to contribute to human asthma. Furthermore, novel differentially expressed
genes (e.g., CXCL13, which is predominantly produced by Th17 cells) as well as dysregulated cellular
pathways including immune cell trafficking, neutrophil chemotaxis, immune and inflammatory
responses, cell cycle regulation, and apoptosis were discovered in allergen-stimulated peripheral blood
mononuclear cells from horses with sEA [9]. MicroRNAs (miRNA) orchestrate many biological and
developmental processes and the top differentially expressed serum miRNAs in horses suggest that
dysregulated pathways are involved in airway remodeling in sEA (e.g., CD4+ T cell function, and a
Th2/Th17-type immune response) [11].
The present study aimed to investigate miRNA and mRNA expression changes in an integrative
analysis in the lung tissue of sEA-affected horses in exacerbation, in remission as well as in healthy
controls. We report dysregulated miRNA-mRNA networks in sEA and interpret the findings in light
of molecular mechanisms described in human asthma and experimental animal models.
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2. Materials and Methods
2.1. Ethics Statement
This study used lung tissue biopsy samples that were archived in the Equine Respiratory
Tissue Biobank (http://www.ertb.ca/) as a product of previous scientific studies [23]. All experimental
procedures were performed in accordance with the Canadian Council for Animal Care guidelines and
were approved by the Animal Care Committee for the Faculty of Veterinary Medicine of the University
of Montreal (Rech-1324).
2.2. Animals, Sample Collection, and Phenotyping
The peripheral lung tissue samples analyzed in this study are a subset of samples published
previously [23]. The samples were provided by the Equine Respiratory Tissue Biobank. Horses that
were part of this study were medically examined by assessing lung function and bronchoalveolar lavage
fluid (BALF) cytology before euthanasia. The horses were part of three cohorts: (1) sEA-affected horses
in exacerbation; (2) sEA-affected horses in remission; and (3) healthy control horses. An overview of
the characteristics and composition of the groups is indicated in Supplementary Note S1.
Inclusion criteria for control horses were the absence of a history of recurrent respiratory distress
and other clinically apparent respiratory or systemic disorders at the time of euthanasia or the preceding
six months. Additionally, control horses were required to show normal eosinophil, neutrophil, and mast
cell levels during BALF cytology examination as well as a normal premortem lung function. A horse
was identified as suffering from sEA only if it demonstrated repeated and reversible episodes of labored
breathing at rest while not showing signs of systemic illness. In addition, an altered lung function,
as well as more than 5% neutrophils during BALF cytology, was a requirement (details on inclusion
criteria are listed in [23]).
Horses with sEA were categorized as in exacerbation or in remission based on the pre-mortem
clinical examination of the lung function as well as the treatment history. Exacerbated horses were
stabled for at least four weeks, fed hay, received no treatment, and showed increased pulmonary
resistance and elastance. Remission horses were kept on pasture for at least four weeks without
treatment and showed normalization of pulmonary resistance and elastance. After euthanasia and
collection of the peripheral lung tissue sample, the samples were snap frozen in liquid nitrogen and
stored at −80 ◦C in RNAlater (Thermo Fisher Scientific, Waltham, MA, USA) until use.
2.3. RNA Extraction and Sequencing
Homogenization of 30 mg of equine lung tissue was carried out using a TissueLyser instrument
(Qiagen, Hilden, Germany) with an oscillation frequency of 25/s for 2 min.
Total RNA extraction was performed using the NucleoSpin miRNA kit (Macherey-Nagel, Düren,
Germany) according to the manufacturer’s protocol. This extraction method allows collecting the
isolated RNA in two separate fractions based on a size limit [one fraction containing small RNA <200 nt)
and one fraction with large RNA (≥200 nt). The quality of all extracts (small and large RNA fraction for
each sample) was assessed using a Bioanalyzer (Agilent, Santa Clara, CA, USA) device. The quantity
of the extracts was determined with a Qubit fluorimeter 2.0 (Invitrogen, Carlsbad, CA, USA).
After having passed the quality and quantity assessments, the small RNA samples were converted
into libraries using the TruSeq Small RNA Library Prep Kit (Illumina, San Diego, CA, USA) following
the manufacturer′s protocol and using a size-selection range of 18 to 30 nt. Single-end sequencing of
the small RNA libraries was carried out on a HiSeq 2500 system (Illumina) with 50 sequencing cycles.
To obtain mRNA libraries, we used the RNA TruSeq Sample Preparation Kit v2 (Illumina), according
to the manufacturer’s protocol. Next-generation sequencing was then carried out on a HiSeq 2500
device (Illumina) on two lanes with 2 × 150 bp paired-end sequencing. The obtained raw data files are
available on Sequence Read Archive as Bioproject PRJNA639022.
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2.4. Bioinformatic Analysis of miRNA Sequencing Data
To analyze the resulting next-generation sequencing dataset of the small RNA fraction containing
the miRNA, we applied a bioinformatics pipeline, which was established during a previously
published project [11]. Briefly, we assessed the raw sequencing data quality using the tool FastQC [24].
Removing adapters and trimming low-quality base calls (<q20) was carried out with the software
cutadapt [25]. The cleaned sequencing reads were aligned to the equine reference genome EquCab3.0 [26]
using the tool miRDeep2 (version 0.0.8) [27]. Subsequently, we detected novel equine miRNA based
on the aligned sequencing reads. To filter low-confidence novel miRNAs, we applied a stringent
miRDeep2 cutoff score of ≥5, as this maximized both the signal-to-noise ratio as well as the estimated
number of true positives. The resulting set of newly detected putative high-quality novel equine
miRNAs was then combined with the set of known equine miRNAs from the database miRBase
(v.22) [28]. The combined set of equine miRNAs was used to quantify the miRNA expression levels
in our sequencing data using the script quantifier.pl of the tool miRDeep2. To detect differentially
expressed miRNAs between the cohorts, the R package DESeq2 [29] was used. We accounted for the
covariates′ sex and RNA extraction batch in the linear model. miRNAs showing a false discovery rate
adjusted p-value (Padjusted) determined by DESeq2 below a threshold of 0.05 were considered to be
significantly differentially expressed. Pathway analysis was carried out using the tool mirPath v.3
using the homologous human miRNAs of the differentially expressed miRNAs [30].
2.5. Bioinformatic Analysis of mRNA Sequencing Data
The raw sequencing reads obtained after the next-generation sequencing of the mRNA libraries
were quality controlled using the tool FastQC. Subsequently, adapters were trimmed, and low-quality
bases (q < 20) were filtered using the software cutadapt. The cleaned sequencing reads were then
aligned to the equine reference genome EquCab3.0 (NCBI Equus caballus Annotation Release 103:
NC_009144.3 1 188260577) with the tool STAR (v.2.5.3a) [31]. Gene expression quantification was carried
out using the tool htseq-count [32]. Differential expression analyses were carried out using DESeq2 and
genes showing a Padjusted ≤ 0.05 were considered to be statistically significantly differentially expressed.
We accounted for the covariates sex and RNA extraction batch in the linear model. Downstream GO
term enrichment was carried out using the tool PANTHER version 14.0 [33].
2.6. Network Analysis of Differentially Expressed miRNAs and mRNAs
As a first method to visualize, explore, and analyze the connection between differential expressed
miRNA and mRNA genes, the software Cytoscape (v3.7.1) [34] was used in combination with the
third-party application CyTargetLinker (v4.1.0) [35]. To construct the networks for all three cohort
comparisons, we applied the same protocol. First, we imported the list of the significant miRNAs
(their respective human homologs), then we expanded these miRNAs with the help of CyTargetLinker
with all their target genes reported by two miRNA–mRNA interaction databases: TargetScan v.7.2 and
miRTarBase v.7.0. Then, we filtered the resulting big network using the list of significantly differentially
expressed genes for the corresponding comparison of two of the study cohorts. These analyses yielded
a network depicting significantly differentially expressed miRNAs and their reported target genes that
were also shown to be differentially expressed. Graphically, we chose to depict the expression levels in
the form of the log2 fold changes as the fill color of the nodes, while we scaled the node size based on
the number of outgoing and ingoing edges.
2.7. Integrative Negative Correlation Analysis of miRNA and mRNA Expression Profiles
To detect significantly negatively correlated expression values between miRNA and mRNA,
we used the tool miRComb [36]. For this analysis, we only used differentially expressed miRNAs (only
known miRNAs) and mRNAs from the three pairwise contrasts applied during differential expression
analyses (exacerbation vs. controls, remission vs. controls, and exacerbation vs. remission). Then,
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we calculated a pairwise Pearson correlation coefficient of the DESeq2 normalized and log2 transformed
expression values. Of these, we kept the significantly negatively correlated miRNA-mRNA pairs
showing a negative Pearson correlation coefficient, and Benjamini–Hochberg corrected p-value ≤ 0.05.
Additionally, to increase the confidence and biological significance of the obtained results, we requested
the miRNA–mRNA interaction to be reported in humans by at least one of four databases (TargetScan,
microCosm, miRDB, and miRSVR).
2.8. Code Availability
All scripts used in the course of this study can be found on GitHub: www.github.com/MaHulliger/
Lung/.
3. Results
3.1. Study Design
This study included eleven clinically phenotyped horses affected by sEA, of which six were
in an exacerbated state and five were in clinical remission. The control group consisted of eight
healthy horses. To investigate potentially dysregulated miRNA-mRNA networks underlying the
pathology of sEA, we applied a comprehensive approach incorporating miRNA expression profiling
and mRNA expression profiling, followed by an integrative miRNA-mRNA negative-correlation
approach (Figure 1).
Figure 1. A schematic illustration of the workflow of this study. sEA, severe equine asthma.
3.2. miRNA Expression Profiles and Novel miRNA Detection in Lung Tissue of Horses
In order to profile the miRNA expression levels in horses, we conducted a high-throughput small
RNA sequencing experiment using sRNA extracts from peripheral lung tissue samples. After assessing
the quality of the obtained data (Supplementary Note S2) and running the pipeline, we detected
Genes 2020, 11, 1143 6 of 34
278 putative high-confidence novel equine miRNAs. Table 1 lists the top 10 novel miRNAs according to
miRDeep2 and the complete list of all putative novel miRNAs is available in Supplementary Table S1.
Table 1. Table of the top 10 putative novel equine miRNAs detected in this dataset ranked according to
decreasing probability of the novel miRNA to be a true positive (represented by the miRDeep2 score;
Supplementary Table S1). Additionally, the number of mismatches and the length of the putative novel
miRNAs in nucleotides, as well as the mature consensus sequences, are indicated.
Provisional Name of
Novel miRNA
Human Homologous
miRNA ID
Number of Mismatches between
Human/Equine miRNA Consensus Mature Sequence
chr6_31290 hsa-let-7a-5p 0/21 ugagguaguaguuugugcuguu
chr20_16763 hsa-miR-30e-3p 2/20 uguaaacacccgacuggaagcc
chrX_37753 - - agagguaaaaaauugauuugacu
chr6_30538 hsa-miR-26b-5p 0/21 uucaaguaauucaggauagguu
chr6_31452 hsa-miR-375-5p 0/22 uuuguucguucggcucgcguga
chr24_19655 hsa-miR-203a-3p 0/22 gugaaauguuuaggaccacuaga
chr2_24882 hsa-miR-320a-3p 0/22 aaaagcuggguugagagggcga
NW_019643269.1_38788 - - gccgaucgaaagggagucgg
chr13_5604 hsa-miR-339-5p 0/22 ucccuguccuccaggagcucacu
chr7_33613 hsa-miR-181c-5p 0/22 aacauucaaccugucggugagu
3.3. Differential miRNA Expression Analyses
The merged set of known equine miRNAs (n = 690) with the set of our putative novel
high-confidence equine miRNAs (n = 278) were used to perform pairwise differential miRNA
expression analyses between the three cohorts (Table 2). A collection of quality control figures for the
miRNA differential expression analyses can be found in Appendix A (Figures A1–A7).
Table 2. Number of statistically significantly differentially expressed miRNAs in all three combinations
of the three cohorts studied.
Exacerbation vs.
Controls
Remission vs.
Controls
Exacerbation vs.
Remission
Number of differentially expressed
miRNAs (Padjusted ≤ 0.05)
8 11 4
3.3.1. Differential miRNA Expression Analysis: sEA-Affected Horses in Exacerbation versus Healthy
Control Horses
Differential expression analysis of miRNAs between horses in an exacerbated state and healthy
control horses yielded 8 miRNAs (Table 3). The miRNA showing the lowest p-value of 6.30 × 10−5 was
eca-miR-142-3p with a log2 fold change of 0.69. In addition to the seven known miRNAs that showed
a significant differential expression pattern, there was one putative novel equine miRNA that was
significantly differentially expressed between the two groups: eca-miR-chrX_37753 (Padjusted = 0.015).
Table 3. Differentially expressed miRNAs comparing horses in an exacerbated state and control horses.
The mean DESeq2 normalized read counts, the log2 fold change, and the adjusted p-values are indicated.
miRNA ID Mean Normalized Read Counts Log2 Fold Change Padjusted
eca-miR-142-3p 7016 0.69 6.30 × 10−5
eca-miR-26a 576,062 −0.38 8.70 × 10−3
eca-miR-142-5p 107,984 0.51 1.00 × 10−2
eca-miR-31 561 2.11 1.20 × 10−2
eca-miR-212 17 2 1.50 × 10−2
eca-miR-223 5088 1.16 1.50 × 10−2
eca-miR-224 10 2.28 1.50 × 10−2
eca-miR-chrX_37753 37,418 0.40 1.50 × 10−2
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3.3.2. Differential miRNA Expression Analysis: sEA-Affected Horses in Remission versus Healthy
Control Horses
Applying the next contrast of sEA-affected horses in remission versus healthy controls, we detected
11 significantly differentially expressed miRNAs. Of these, five were novel, while six where
known equine miRNAs (Table 4). The miRNA with the lowest p-value of 2.52 × 107 and the one
with the highest log2 fold change (3.36) was a putative novel miRNA with the provisional ID
eca-miR-NW_019643269.1_38788.
Table 4. Differentially expressed miRNAs comparing asthmatic horses in remission and control horses.
The mean DESeq2 normalized read counts, the log2 fold change, and the adjusted p-values are indicated.
miRNA ID Mean Normalized Read Counts Log2 Fold Change Padjusted
eca-miR-NW_019643269.1_38788 3512 3.36 2.52 × 10−7
eca-miR-142-3p 7016 0.63 1.00 × 10−3
eca-miR-142-5p 107,984 0.59 2.00 × 10−3
eca-miR-chr15_8716 20 −2.57 2.00 × 10−3
eca-miR-chr7_32350 2186 −2.01 7.00 × 10−3
eca-miR-chrX_37117 790 −1.76 7.00 × 10−3
eca-miR-363 453 −0.61 2.70 × 10−2
eca-miR-379 16 −1.97 2.70 × 10−2
eca-miR-193a-3p 430 1.02 3.00 × 10−2
eca-miR-chr6_31338 323 −1.53 3.00 × 10−2
eca-miR-223 5093 1.04 4.60 × 10−2
3.3.3. Differential miRNA Expression Analysis: sEA-Affected Horses in Exacerbation Versus
sEA-Affected Horses in Remission
The third and final differential miRNA expression analysis was carried out comparing affected
horses in exacerbation against affected horses in remission. We identified four differentially expressed
miRNAs (Table 5). The miRNA showing the lowest Padjusted and the lowest negative log2 fold change
(−2.6) again was the putative novel miRNA with the provisional ID eca-miR-NW_019643269.1_38788
with a Padjusted of 6.00 × 10−3. The three remaining significantly differentially expressed miRNAs were
eca-miR-146-5p, eca-miR-135b, and eca-miR-31.
Table 5. Differentially expressed miRNAs comparing asthmatic horses in exacerbation and asthmatic
horses in remission. The mean DESeq2 normalized read counts, the log2 fold change, and the adjusted
p-values are indicated.
miRNA ID Mean Normalized Read Counts Log2 Fold Change Padjusted
eca-miR-NW_019643269.1_38788 3512 −2.6 6.00 × 10−3
eca-miR-146b-5p 7515 2.3 9.00 × 10−3
eca-miR-135b 14 4.08 4.60 × 10−2
eca-miR-31 560 2.17 4.60 × 10−2
Considering all three comparisons, a total of six putative novel equine miRNAs were detected to
be significantly differentially expressed. While three of these miRNAs have a clear human homologous
miRNA (eca-miR-chr15_8716, eca-miR-chr7_32350, and eca-miR-NW_019643269.1_38788), two novel
miRNAs showed an identical seed sequence (nucleotides 2 to 8 at the 5′ end), but low percent
identity to human miRNAs (eca-miR-chrX_37117 and eca-miR-chr6_31338). For the remaining
miRNA (eca-miR-chrX_37753), the similarity to human miRNAs was very limited, however, a bovine
homologous miRNA was reported (Table 6).
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Table 6. Differentially expressed putative novel equine miRNAs in any of the three group comparisons.
The miRDeep2 given provisional miRNA ID, the consensus sequence of the novel equine miRNA,
as well as a potential human homologous miRNA ID are listed.
Provisional miRNA ID Consensus Sequence Homologous miRNA Percent Identity
eca-miR-NW_019643269.1_38788 gccgaucgaaagggagucgg hsa-miR-5006-3p 93.8% (identical seed)
eca-miR-chr15_8716 accuggggaucugaggagg hsa-miR-6852-5p 93.8% (identical seed)
eca-miR-chr7_32350 aucccaccacugccacca hsa-miR-1260a 94.4% (identical seed)
eca-miR-chrX_37117 uuccccggcaucuccucca hsa-miR-6763-3p 42.1% (identical seed)
eca-miR-chr6_31338 uccccggcuccuccacca hsa-miR-4707-5p 38.9% (identical seed)
eca-miR-chrX_37753 agagguaaaaaauugauuugacu bta-miR-6119-5p 100% (identical seed)
Figure 2 shows the Venn diagram comparing the potential overlaps of identified differential
expressed miRNAs between the three cohorts.
Figure 2. Venn diagram of differentially expressed miRNAs of the three comparisons: exacerbation
(EXAC) vs. control (CTL), remission (REM) vs. CTL, and EXAC vs. REM. Shared between EXAC vs.
CTL and EXAC vs. REM was eca-miR-31, while eca-miR-NW_019643269.1_38788 was shared between
REM vs. CTL and EXAC vs. REM. Three miRNAs were shared by two comparisons (exacerbation vs.
control and remission vs. control): eca-miR-142-3p, eca-miR-142-5p, and eca-miR-223.
3.4. Pathway Analysis of Differentially Expressed miRNAs and Their Target Genes
Pathway analysis using the human homologous miRNAs of the differentially expressed miRNAs
of all three contrasts and experimentally confirmed target genes from Tarbase v7 that are potentially
relevant for the molecular pathology of sEA yielded several significantly enriched pathways (e.g., TGF-β
signaling, PI3K-Akt signaling, FoxO signaling, and T cell receptor signaling). Supplementary Note S3
lists the results of these analyses in detail.
3.5. mRNA Expression Profiles in Lung Tissue of Horses and Differential Gene Expression Analyses
Detailed quality control of the raw mRNA sequencing data was carried out before applying the
analytical pipeline (Supplementary Note S4). Analogous to the miRNA differential expression analyses,
pairwise differentially expressed mRNAs between the three conditions were identified (Table 7). A set
of quality control figures can be found in Appendix A (Figures A8–A11).
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Table 7. Number of statistically significantly differentially expressed genes in all three combinations of
the three cohorts studied.
Exacerbation vs.
Controls
Remission vs.
Controls
Exacerbation vs.
Remission
Number of differentially expressed
genes (Padjusted ≤ 0.05)
274 53 257
3.5.1. Differential mRNA Expression Analysis: sEA-Affected Horses in Exacerbation Versus Healthy
Control Horses
Applying the first contrast, comparing asthmatic horses in exacerbation to healthy controls,
we identified a total of 274 significantly differentially expressed genes (Table 8, Supplementary
Table S5). Of the significant genes, 169 were upregulated and 105 genes were determined to be
downregulated in horses in an exacerbated state compared with control horses.
Table 8. Top 20 significantly differentially expressed genes between asthmatic horses in exacerbation
and healthy horses according to the Padjusted. The normalized mean expression values calculated by
DESeq2, the log2 fold change, as well as the adjusted p-values are listed.
Gene Name Normalized Mean Expression Value Log2 Fold Change Padjusted
HSPB7 374 2.60 3.26 × 10−7
LOC100056936 814 4.33 2.53 × 10−6
LOC100056698 1050 3.71 3.65 × 10−6
GSTA1 321 5.73 4.41 × 10−6
CXCL6 840 5.23 6.63 × 10−6
PMEPA1 1042 0.81 7.73 × 10−6
S100A12 2715 4.09 4.58 × 10−5
IGFBP3 1063 4.02 7.04 × 10−5
LOC100630497 73 −1.39 9.63 × 10−5
CADM3 297 4.04 1.18 × 10−4
AP2A1 1463 0.38 1.46 × 10−4
SAA1 2773 2.70 1.46 × 10−4
SCN1B 106 1.64 1.46 × 10−4
S100G 41 −1.71 3.00 × 10−4
LOC111768320 74 1.42 3.06 × 10−4
PTPRQ 30 −2.58 3.27 × 10−4
LOC111773141 10 2.63 5.07 × 10−4
PCDH15 35 2.64 5.07 × 10−4
IL1R2 159 3.68 5.76 × 10−4
The upregulated differentially expressed genes showed a mean log2 fold change of +5.4 (±0.4 sd)
and the downregulated differentially expressed genes exhibited a mean log2 fold change of −3.67
(±0.90 sd). Of these differentially expressed genes, 46 have previously been associated with asthma in
humans (according to disGeNET v6.0; Supplementary Note S5).
3.5.2. Differential mRNA Expression Analysis: sEA-Affected Horses in Remission Versus Healthy
Control Horses
The second comparison covering asthmatic horses in remission and healthy control horses yielded
a total of 53 significantly differentially expressed (Table 9, Supplementary Table S7). Of these, 32 were
upregulated in horses in remission relative to healthy control horses and 21 genes were downregulated.
The upregulated differentially expressed genes showed a mean log2 fold change of 1.20 (±0.77 sd),
while the downregulated differentially expressed genes presented a mean log2 fold change of −1.09
(±0.50 sd).
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Table 9. Top 20 significantly differentially expressed genes between asthmatic horses in remission and
healthy horses according to the adjusted p-value. The normalized mean expression values calculated
by DESeq2, the log2 fold change, as well as the adjusted p-values are listed.
Gene Name Normalized Mean Expression Value Log2 Fold Change Padjusted
YBX3 3635 0.90 2.79 × 10−5
TLR3 612 −0.62 1.86 × 10−4
LOC111771691 63 0.80 3.62 × 10−4
TMEFF2 41 −3.23 3.62 × 10−4
CXHXorf21 100 −1.03 6.87 × 10−4
EFHD1 86 2.36 8.87 × 10−4
RPL35 3594 0.66 4.08 × 10−3
MX2 404 −1.1 4.12 × 10−3
NR3C2 839 −0.63 5.87 × 10−3
POLG2 325 0.93 5.87 × 10−3
DDX60 1838 −0.94 6.44 × 10−3
F2RL2 1480 0.6 6.44 × 10−3
MAPKAP1 854 0.37 6.44 × 10−3
TTC19 491 0.40 6.44 × 10−3
URI1 1477 0.37 7.78 × 10−3
ADM2 80 −0.91 8.08 × 10−3
LOC102147438 100 0.7 8.08 × 10−3
DACH2 153 −1.8 8.73 × 10−3
TRIM17 82 1.19 8.73 × 10−3
3.5.3. Differential mRNA Expression Analysis: sEA-Affected Horses in Exacerbation versus
sEA-Affected Horses in Remission
Finally, we performed a differential gene expression analysis for the last contrast between the three
groups: asthmatic horses in an exacerbated state against asthmatic horses in remission. This analysis
yielded a total of 257 significantly differentially expressed genes between the two groups (Table 10,
Supplementary Table S8). A total of 180 genes were significantly upregulated in horses in an exacerbated
state relative to horses in remission, while 77 genes were significantly downregulated. The observed
mean log2 fold change of the significantly upregulated genes was 2.95 (±2.26 sd), while the mean log2
fold change of the downregulated genes was −0.56 (±0.51 sd).
Table 10. Top 20 significantly differentially expressed genes between asthmatic horses in an exacerbated
state and asthmatic horses in remission according to the adjusted p-value. The normalized mean
expression values calculated by DESeq2, the log2 fold change, as well as the adjusted p-values are listed.
Gene Name Normalized Mean Expression Value Log2 Fold Change Padjusted
LOC100630497 73 −1.94 1.75 × 10−7
CADM3 297 4.85 6.37 × 10−5
FOXL1 77 1.27 6.37 × 10−5
LOC111771691 63 −0.95 6.37 × 10−5
TFF1 3983 9.14 1.95 × 10−4
LOC106781592 6117 8.91 2.13 × 10−4
CXCL6 840 5.06 6.16 × 10−4
LOC111770812 41 3.56 6.16 × 10−4
LOC111771553 194 −0.89 6.16 × 10−4
TNF 130 −1.16 6.16 × 10−4
A2ML1 1662 5.32 8.43 × 10−4
IGFBP3 1063 4.15 8.43 × 10−4
TMEM260 1562 −0.46 8.43 × 10−4
ATP8B1 1301 1.01 9.97 × 10−4
IL1R2 159 4.16 1.03 × 10−3
CCL19 103 2.37 1.25 × 10−3
TCN1 599 7.24 1.25 × 10−3
ST6GAL2 447 6.09 1.55 × 10−3
LOC111768320 74 1.5 1.80 × 10−3
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To investigate potential overlaps of the three sets of significantly differentially expressed genes,
we created a visualization of the overlaps in the form of a Venn diagram (Figure 3).
Figure 3. Venn diagram of the three sets of differentially expressed genes between the three comparisons:
‘exacerbation (EXAC) vs. controls (CTL)’, ‘remission (REM) vs. controls’, and ‘exacerbation vs.
remission’. The three overlapping sets shared between two contrasts varied from 9 to 77 genes
(Supplementary Table S9).
3.6. Gene Ontology (GO)-Term Enrichment Analysis of Differentially Expressed mRNAs
To check functional enrichment of the reported sets of differentially expressed genes, we used
PantherDB to perform gene ontology (GO) term enrichment analysis. The enriched GO-terms for the
comparison between horses in an exacerbated state and control horses mostly spanned inflammatory
processes and pathways related to tissue remodeling (Figure 4). The significant GO-term with the lowest
adjusted p-value was “inflammatory response”, with 18 differentially expressed genes involved. For the
analysis comparing horses in an exacerbated state to horses in remission, the significantly enriched
GO-terms mostly represented stress response and developmental pathways (Figure 4). The GO-term
with the lowest adjusted p-value was “response to stress”, including 44 differentially expressed genes.
Owing to the comparably low number of differentially expressed genes in the last contrast comparing
horses in remission to healthy horses, no GO-terms were detected to be significantly enriched.
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Figure 4. Gene ontology (GO)-term enrichment analyses indicating the adjusted p-value of the enriched
terms. (A) Enriched GO-terms using differentially expressed genes between horses in an exacerbated
state and control horses. (B) Enriched Go-terms using differentially expressed genes between horses in
an exacerbated state and horses in remission.
3.7. Network Analyses of Differentially Expressed miRNAs and mRNAs
In order to visualize the reported sets of differentially expressed miRNAs and mRNAs,
we constructed a network for all three pairwise comparisons. We used two miRNA–mRNA interaction
databases (TargetScan and miRTarBase). For the network analysis, we only included differentially
expressed genes that were reported to be targets of at least one differentially expressed miRNA.
With this approach, we aimed to investigate potentially dysregulated miRNA-mRNA networks that
might underlie the pathophysiology of sEA.
3.7.1. Network Analysis: sEA-Affected Horses in Exacerbation versus Healthy Control Horses
The first constructed network (exacerbation vs. controls) showed miR-142-5p and miR-26a-5p
as major hubs regulating several mRNAs (Figure 5). The network shows several genes regulated by
more than one miRNA (CCNT2, SCD, MEX3A, FRMPD4, SYDE2, RGS4, GRB10, TMEM260, ST3GAL6,
HTR2A, and HAS3). These genes might be an interesting starting point for future research into asthma
exacerbation. To study this synergistic network in more detail, we expanded the resulting network with
transcription factors interacting with genes in the network (Supplementary Figure S1) and annotated it
with biological pathways (Supplementary Figure S2). This analysis revealed, for example, that the
transcription factors STAT3 (which is a key transcription factor in Th17 cellular development [37]),
GATA2, and NFKB1 might play an important role in this molecular network. Additional potentially
affected biological pathways detected were the following: IL-4 signaling pathway, IL-17 signaling
pathway, TGF-β signaling, NOTCH signaling, and the development of pulmonary dendritic cell and
macrophage subsets.
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Figure 5. miRNA-gene interaction network using the set of differentially expressed miRNAs and
mRNAs between asthmatic horses in exacerbation and healthy controls. The color of the interior of the
nodes represents the reported log2 fold change of the miRNA or gene, the node shape represents the
feature type (miRNA: circle, target gene: square), and the node size represents the degree (number of
in- and outgoing edges). Two arrows between two nodes indicate that the interaction is supported by
both databases (e.g., between miR-31-5p and SYDE2).
3.7.2. Network Analysis: sEA-Affected Horses in Remission versus Healthy Control Horses
The second network from the comparison of sEA-affected horses in remission to healthy controls
was rather limited, because of the lower number of significant mRNAs detected (Figure 6). However,
ARID1B, regulated by two differentially expressed miRNAs, presents itself as a potential target for
investigating the molecular mechanism of the long-term response in asthmatic horses in remission.
Figure 6. miRNA-gene interaction network using the set of differentially expressed miRNAs and
mRNAs between asthmatic horses in remission and healthy controls. The color of the interior of the
nodes represents the reported log2 fold change of the miRNA or gene, the node shape represents the
feature type (miRNA: circle, target gene: square), and the node size represents the degree (number of
in- and outgoing edges).
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3.7.3. Network Analysis: sEA-Affected Horses in Exacerbation versus sEA-Affected Horses
in Remission
The third and final constructed network indicated a potential prominent role for the highly
overexpressed ST6GAL2 in resolution of acute airway inflammation (as this covers the comparison of
asthmatic horses in exacerbation to asthmatic horses in remission). Interestingly, most target genes in
the network are overexpressed in asthmatic horses in exacerbation (Figure 7). We also expanded this
resulting network with transcription factor–gene interactions (Supplementary Figure S3) and biological
pathways (Supplementary Figure S4).
Figure 7. miRNA-gene interaction network using the set of differentially expressed miRNAs and
mRNAs between affected horses in exacerbation and remission. The color of the interior of the nodes
represents the reported log2 fold change of the miRNA or gene, the node shape represents the feature
type (miRNA: circle, target gene: square), and the node size represents the degree (number of in- and
outgoing edges).
3.8. Identification of Putative miRNA-mRNA Regulatory Interactions Associated with sEA
3.8.1. Identification of Negatively Correlated miRNA-mRNA Pairs: sEA-Affected Horses in
Exacerbation versus Healthy Control Horses
For the first contrast, we calculated pairwise Pearson’s correlation between all possible
combinations of the 274 differentially expressed (DE) genes, and the seven differentially expressed
miRNAs (novel miRNAs were not used for these analyses). Applying this approach, we were able to
detect 14 significantly negatively correlated miRNA-mRNA pairs showing a mean Pearson’s correlation
coefficient of −0.75 (±0.08 sd) (Table 11).
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Table 11. This table displays the significantly negatively correlated miRNA-mRNA pairs for the
comparison of horses in exacerbation and control horses. Pearson’s correlation coefficient and Padjusted
are indicated.
DE miRNA DE mRNA Pearson’s Correlation Coefficient Padjusted
miR-31-5p SYDE2 −0.91 4.00 × 10−4
miR-26a-5p RGS4 −0.88 8.00 × 10−4
miR-224-5p FBXL3 −0.82 2.80 × 10−3
miR-26a-5p CA2 −0.78 6.20 × 10−3
miR-142-3p CCNT2 −0.77 6.60 × 10−3
miR-142-3p ADAM22 −0.76 7.90 × 10−3
miR-142-3p CYP1A1 −0.73 1.20 × 10−2
miR-142-3p PPM1K −0.71 1.50 × 10−2
miR-212-3p FAM76B −0.71 1.60 × 10−2
miR-224-5p SLC25A36 −0.71 1.60 × 10−2
miR-142-3p VPS13A −0.70 1.90 × 10−2
miR-142-5p VPS13A −0.68 2.30 × 10−2
miR-142-3p SIAH1 −0.65 3.30 × 10−2
miR-142-5p CCNT2 −0.63 4.10 × 10−2
3.8.2. Identification of Negatively Correlated miRNA-mRNA Pairs: sEA-Affected Horses in Remission
versus Healthy Control Horses
Applying the same pipeline to the 53 differentially expressed genes and six known differentially
expressed miRNAs detected between asthmatic horses in remission and healthy control horses revealed
four miRNA–mRNA pairs that were significantly negatively correlated. eca-miR-142-3p showed
negatively correlated expression values with three putative target genes: ADAM22, GORAB, and NR3C2.
The mean Pearson’s correlation coefficient obtained for all detected pairs was −0.78 (±0.09 sd) (Table 12).
Table 12. Statistically significantly negatively correlated miRNA–mRNA pairs for the comparison
of asthmatic horses in remission and control horses. Pearson’s correlation coefficient and adjusted
p-values are indicated.
DE miRNA DE mRNA Pearson’s Correlation Coefficient Padjusted
eca-miR-142-3p ADAM22 −0.92 1.00 × 10−3
eca-miR-142-3p GORAB −0.78 1.70 × 10−2
eca-miR-142-5p ARID1B −0.71 3.30 × 10−2
eca-miR-142-3p NR3C2 −0.69 3.70 × 10−2
3.8.3. Identification of Negatively Correlated miRNA-mRNA Pairs: sEA-Affected Horses in
Exacerbation Versus sEA-Affected Horses in Remission
For the last contrast analyzed, we used the 257 differentially expressed genes and the three
differentially expressed known miRNAs of the comparison between asthmatic horses in an exacerbated
state and asthmatic horses in remission. This analysis revealed two significant negatively correlated
miRNA–mRNA pairs: eca-miR-146b-5p with OSGIN2, as well as the same miRNA with the gene
UBTD2 with a Pearson’s correlation coefficient of −0.82 (Table 13).
Table 13. Significant negatively correlated miRNA–mRNA pairs for the comparison of asthmatic
horses in an exacerbated state and asthmatic horses in remission. Pearson’s correlation coefficient and
adjusted p-values are indicated.
DE miRNA DE mRNA Pearson′s Correlation Coefficient Padjusted
eca-miR-146b-5p OSGIN2 −0.82 4.7 × 10−2
eca-miR-146b-5p UBTD2 −0.82 4.7 × 10−2
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4. Discussion
In this study, we identified molecular mechanisms and pathways that may play important
roles in the pathogenesis of sEA and offer novel comparative data for human asthma research
based on comprehensive global miRNA and mRNA expression profiling in lung tissue samples
of sEA-affected horses in exacerbation, in remission, and in healthy controls. To the best of our
knowledge, this is the first study using an integrative approach combining miRNA and mRNA
expression profiles in a spontaneous model of asthma. Dysregulated miRNA-mRNA networks were
identified, revealing novel and striking similarities at the transcriptomic level between sEA and human
asthma pheno- and endotypes (particularly severe neutrophilic asthma) based on in-depth literature
research (Supplementary Table S10).
Some of the most prominent findings relate to inflammatory processes documented in severe
neutrophilic asthma of humans. We decided to focus on the three miRNAs (miR-142-3p, miR-142-5p,
and miR-223) that were found to be upregulated in both comparisons, asthmatic horses in exacerbation
versus healthy controls and horses in remission versus controls (Figure 2). Two of these miRNAs,
namely miR-142-3p and miR-223, play a central role in the molecular pathology of human severe
neutrophilic asthma by promoting airway inflammation and obstruction [38]. It was not only shown
that these two miRNAs are overexpressed in the sputum of humans with severe neutrophilic asthma, but
also that their overexpression is strongly associated with inflammatory parameters, airway obstruction,
and proinflammatory cytokine levels [38]. Validated target genes of these miRNAs are implicated in
several inflammatory pathways including Toll-like receptor signaling, NOD-like receptor signaling,
and mitogen-activated protein kinase (MAPK) signaling, leading to increased levels of IL-1β, IL-6,
and IL-8 [38]. There was a significant increase in the corresponding IL-1β and IL-8 levels in patients
with severe asthma [38]. Furthermore, the expression levels were correlated with the neutrophil counts
in the sputum samples. Several studies reporting increased expression levels of IL-1β and IL-8 in
humans with neutrophilic asthma agree with these results [39,40]. Interestingly, these pathways and
signature genes also are consistent with findings in horses with sEA, including recent transcriptomic
analyses of the bronchial epithelium of affected horses relative to healthy horses in response to antigen
challenge [22] and several other studies reporting overexpressed IL-1β and IL-8 [17,41–44].
Although the exact molecular mechanism of how these two miRNAs affect the pathophysiology
of severe neutrophilic asthma remains unknown, recent findings point towards their role in the
development of other important disorders: in the lungs of tuberculosis patients, miR-223 upregulates
miR-142-3p expression as part of the ‘miR-223-CEBP-β-LMO2-miR-142’ pathway [45] and controls
neutrophil recruitment as well as neutrophil-driven inflammation [39]. Furthermore, miR-223 plays
an essential role in autoimmune inflammation, where it mediates the myeloid dendritic cell induced
pathologic Th17 response [46]. Its targeting of the inflammatory mediator ICAM1 [47] and its effect on
macrophage polarization towards the M2 type [48] suggest additional important functions of miR-223
in neutrophilic asthma. Furthermore, miR-142-3p is implicated in aberrant WNT signaling during
airway remodeling [49], in pro-inflammatory processes via monocyte-derived dendritic cells (while
suppressing Treg expansion) [50], and in the suppression of Th1 cytokines by dendritic cells [51].
Additionally, miR-142-3p is overexpressed in Lipopolysaccharide (LPS)-stimulated macrophages [52]
and impairs antigen processing [53]. Thus, dysregulated miR-223 and miR-142-3p might affect sEA
pathophysiology by promoting airway remodeling, positively regulating neutrophil recruitment and
airway inflammation, and possibly affecting macrophage polarization. MiR-223, together with miR-31,
showed an interesting pattern of a rather high within-group variation for horses in exacerbation
(Appendix A Figure A5). While this might be expected owing to the symptomatic stage of the disease,
it might also reflect the presence of potential unidentified endotypes of sEA.
Several differentially expressed miRNAs detected in the lungs of horses in exacerbation compared
to controls are linked with the positive regulation of the Th17 pathway. Indeed, downregulated miR-26a
leads to increased expression of IL-17 and IL-6 [54] and affects Th17/Treg balance towards Th17 cells [55].
Additionally, miR-31 drives Th17 cell differentiation through targeting IL-25, while suppressing
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Treg differentiation through FOXP3 [56]. Moreover, miR-212 promotes Th17 cell differentiation
likely by targeting Bcl-6 [57], while miR-223 regulates the Th17 immune response in a myeloid
dendritic cell-driven manner [46]. The potential involvement of an increased Th17-type immune
response is further supported by multiple dysregulated miRNAs in the second contrast comparing
sEA-affected horses in remission to healthy horses (miR-363, miR-379, miR-193a-3p, miR-135b [58–62]).
Th17 cells recruit neutrophils through releasing Th17 cytokines (IL-17A, IL17F, and IL-22) and
epithelial-derived neutrophilic chemokines [63]. Interestingly, the miRNA–mRNA networks that we
expanded with regulatory transcription factor interactions support the hypothesis of a dysregulated
Th17 cell differentiation pathway (Supplementary Figures S1 and S2). The expanded network suggests
an important role for the IL-17 signaling pathway and for STAT3, which is a key transcription
factor in Th17 cellular development. Taken together, these findings suggest an important role of the
Th17 pathway in the pathophysiology of sEA, especially in disease exacerbation. The dysregulated
miRNAs presented in this study might affect sEA pathology by leading to increased recruitment and
differentiation of Th17 cells in the lung and increased Th17 cell differentiation. The Th17-mediated
inflammation then in turn potentially leads to increased neutrophilic airway inflammation and increased
airway remodeling [63]. This agrees with our previous findings in stimulated PBMC and those of other
groups in mediastinal lymph nodes, BALF, and epithelial cells of sEA-affected horses [9,11,64–66].
However, previous findings in sEA also suggest that Th2-type immune responses consistent with
allergic-type asthma play a role in sEA [12–14], and some of our present results support this pathway.
Differential gene expression analysis showed hundreds of genes to be significantly differentially
expressed between the three group comparisons. IL4R was among the significantly differentially
expressed genes of the first comparison (exacerbation against controls) and is also on the list of genes
previously associated with human asthma (Supplementary Table S6). IL4R, which codes for the
cytokine receptor binding the Th2 cytokines IL-4 and IL-13, was previously identified by our group as
a candidate gene for sEA in a GWAS experiment [67]. Our network analysis, expanded with annotated
pathways (Supplementary Figure S2), also supports involvement of the IL-4 signaling pathway in sEA.
Of note, our integrative analysis of miRNA–mRNA pairs further substantiates the role of the Th2-type
response during sEA exacerbation. Carbonic anhydrase II (CA2), which was negatively correlated
with miR-26a-5p and significantly upregulated in exacerbated horses, is known to be upregulated
by Th2 cytokines like IL-4 and IL-13, and reportedly promotes airway hyperresponsiveness [68,69].
Moreover, RGS4 (also negatively correlated with miR-26a-5p) plays a role in modulating airway
hyper-responsiveness and airway obstruction [70,71].
Our results suggest additional dysregulated processes in sEA exacerbation including alternative
macrophage activation (miR-26a, miR-142-5p, miR-212, miR-223 [48,52]) and NF-kB signaling
(miR-224 [72]). The latter being additionally supported by our expanded transcription factor–gene
interaction network analysis (Supplementary Figure S1) and by earlier studies investigating
sEA [11,73,74]. Importantly, our miRNA–mRNA integrative analysis also indicates that NF-kB plays an
important role in sEA: CYP1A1 was negatively correlated with miR-142-3p. This NF-kB controlled gene
has been associated with asthma and lung function deficits [75,76]. Additionally, SIAH-1 (targeted
by miR-142-3p) regulates NF-kB activity via TNF-α and has been shown to interact with many other
genes involved in the mammalian immune response [77].
Counteracting these deleterious processes, we also identified anti-inflammatory pathways taking
place during asthma exacerbation, but not in remission. MiR-146-5p targets inflammatory mediators
like COX2, IL-1β, KIT, NFKB1, TLR4, TRAF6, and UHRF1 [78] and has been proposed as a predictor for
asthma exacerbations in childhood asthma [79,80]. The anti-inflammatory miR-135b acts by targeting
FOXN3 and RECK, an inhibitor of MMP2, and the known sEA pathogenesis factor MMP9 [81–83].
These anti-inflammatory actions might be the immunological counterbalance, and thus the defense
mechanism of the lung against acute inflammation (likely Th17-mediated, as outlined above) during
disease exacerbation.
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Paralleling the pathology of severe human asthma [84], the significantly dysregulated miRNAs
(miR-363, miR-379, miR-193a-3p) found in sEA-affected horses in remission (when compared with
healthy horses) are likely to enhance TGF-β signaling [58–60]. This is further supported by the expanded
network analysis including annotated pathways (Supplementary Figure S2). Thus, these miRNAs
may be key players in airway remodeling during disease remission, prolonging and amplifying effects
of miRNAs that were significantly upregulated in exacerbation. Specifically, miR-26a, miR-142-3p,
and miR-142-5p promote airway remodeling (in parts by positively affecting TGF-β pathways) [55,85].
Besides the miRNA–mRNA pairs discussed above, our integrative miRNA–mRNA expression
analysis revealed numerous negatively correlated pairs implicated in sEA. Many of these have
not yet been investigated regarding a potential role in asthma pathology. Because we detected
the miRNA–mRNA pair ADAM22-miR-142-3p in both comparisons (exacerbation vs. controls and
remission vs. controls), it might be a key player in the pathophysiology of sEA that not only affects
exacerbation of the disease, but also disease remission. Additionally, we constructed miRNA–mRNA
networks as an alternative approach. This visual representation helped to put some of the negatively
correlated miRNA–mRNA pairs in a bigger perspective. Besides the pair ADAM22-miR-142-3p,
the genes CCNT2 (paired with miR-142-5p and miR-142-3p), SIAH1, RGS4 (negatively correlated
with miR-26a-5p), and SYDE2 (paired with miR-31-5p) represent promising starting points for future
research to validate the role of these dysregulated pathways in functional experiments.
Additionally, future research could be applied to validate our findings in an independent and larger
study cohort, as well as by applying different technical approaches (e.g., RT-qPCR). While differential
expression analyses with six or more samples per group are considered robust [86], an increased
sample size can increase statistical power, and thus the ability to detect more differentially expressed
genes and miRNAs.
In conclusion, we found important similarities between sEA (at the transcriptomic level) and severe
neutrophilic asthma in humans. Specifically, our findings suggest that the dysregulated miRNAs and
mRNAs might lead to a predominantly Th17-mediated immune response in exacerbation and remission
of sEA. This Th17-mediated inflammation could potentially explain the prominent role of neutrophils
in sEA. Other main findings also show parallels with allergic asthma (Th2-type response), and present
potential pathways that promote airway remodeling. These results expand our understanding of the
molecular mechanisms that underlie airway hyper-responsiveness and bronchospasm during disease
exacerbation and airway remodeling during disease remission.
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Appendix A
Figure A1. Principal component analysis (PCA) plot using the miRNA raw data. The labels of the data
points indicate sample IDs.
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Figure A2. Quality control plots for the differential miRNA expression analysis using the contrast of
horses in exacerbation vs. healthy control horses. An MA-plot (A), a Volcano plot (B), and a histogram
of the obtained p-values (C) are shown. Non-significant (NS) miRNAs are indicated in grey color.
Genes 2020, 11, 1143 21 of 34
Figure A3. Quality control plots for the differential miRNA expression analysis using the contrast of
horses in remission vs. healthy control horses. An MA-plot (A), a Volcano plot (B), and a histogram of
the obtained p-values (C) are shown. Non-significant (NS) miRNAs are indicated in grey color.
Genes 2020, 11, 1143 22 of 34
Figure A4. Quality control plots for the differential miRNA expression analysis using the contrast of
horses in exacerbation vs. horses in remission. An MA-plot (A), a Volcano plot (B), and a histogram of
the obtained p-values (C) are shown. Non-significant (NS) miRNAs are indicated in grey color.
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Figure A5. Obtained normalized read counts for all differentially expressed miRNAs for the contrast
exacerbation vs. controls. The red dot indicates the mean expression value and the red bars span the
range of plus and minus one standard deviation. Adjusted p-values are listed for the contrast of interest.
Genes 2020, 11, 1143 24 of 34
Figure A6. Obtained normalized read counts for all differentially expressed miRNAs for the contrast
remission vs. controls. The red dot indicates the mean expression value and the red bars span the range
of plus and minus one standard deviation. Adjusted p-values are listed for the contrast of interest.
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Figure A7. Obtained normalized read counts for all differentially expressed miRNAs for the contrast
exacerbation vs. remission. The red dot indicates the mean expression value and the red bars span the
range of plus and minus one standard deviation. Adjusted p-values are listed for the contrast of interest.
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Figure A8. (A) Principal component analysis (PCA) plot using the mRNA raw data using the top 500
most variable genes. The labels of the data points indicate sample IDs. (B) Boxplots illustrating cook’s
distances for each sample across all genes. The numbers in the labels represent sample IDs.
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Figure A9. Quality control plots for the differential mRNA expression analysis using the contrast of
horses in exacerbation vs. healthy control horses. An MA-plot (A), a Volcano plot (B), and a histogram
of the obtained p-values (C) are shown. Non-significant (NS) genes are indicated in grey color.
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Figure A10. Quality control plots for the differential mRNA expression analysis using the contrast of
horses in remission vs. healthy control horses. An MA-plot (A), a Volcano plot (B), and a histogram of
the obtained p-values (C) are shown. Non-significant (NS) genes are indicated in grey color.
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Figure A11. Quality control plots for the differential mRNA expression analysis using the contrast of
horses in exacerbation vs. horses in remission. An MA-plot (A), a Volcano plot (B), and a histogram of
the obtained p-values (C) are shown. Non-significant (NS) genes are indicated in grey color.
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